20 mg (Scored tablets)


Each tablet contains 20 mg rosuvastatin.

Mechanism of action:
(Statirose) Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase. 
(Statirose) Rosuvastatin increases the number of hepatic LDL receptors on the cell-surface, enhancing uptake and catabolism of LDL 
(Statirose) Rosuvastatin inhibits the hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles. 


Therapeutic indications:

  • Treatment of hypercholesterolemia.
  • Prevention of Cardiovascular Events.


Treatment of hypercholesterolaemia: 

The recommended start dose is 10-20 mg orally once daily. 
Dose adjustment to the next dose level can be made after 4 weeks, if necessary.
Prevention of cardiovascular events:

in the cardiovascular events risk reduction study, the dose used was 20 mg daily.
Statirose may be given at any time of day, with or without food.


Statirose is contraindicated:

  • In patients with hypersensitivity to rosuvastatin or to any of the excipients. 
  • In patients with active liver disease including unexplained, persistent elevations of serum transaminases and any serum transaminase elevation exceeding 3 x the upper limit of normal (ULN). 
  • In patients with severe renal impairment (creatinine clearance <30 ml/min). 
  • In patients with myopathy. 
  • In patients receiving concomitant cyclosporine.
  • During pregnancy and lactation and in women of childbearing potential not using appropriate contraceptive measures.


10 scored tablets/strip.